Response Rates 2 Hours Following Treatment of Initial Headache in Adolescents

Response rates 2 hours following treatment of initial

This preview shows page 72 - 95 out of 95 pages.

Table 4.: Response Rates 2 Hours Following Treatment of Initial Headache in Adolescents age 12-17 years Placebo ALMOTRIP 6.25 mg ALMOTRIP 12.5 mg Study 1 55.3% (n/N = 94/170) 71.8%* (n/N = 127/177) 72.9% (n/N = 132/181)
Image of page 72
Figure 3. Estimated Probability of Achieving an Initial Headache Response (mild or no pain) in 2 Hours in the adolescent study The prevalence of the migraine-associated symptoms (nausea, photophobia, and phonophobia) at 2 hours after taking the dose was not significantly different between patients who received AXERT 6.25 mg or 12.5mg and those who received placebo.
Image of page 73
COMPETITORS
Image of page 74
FORM PRICE COMPANY REMARKS IMIGRAN* (Sumatriptan) 50,100 mg Film Coated Tablet -50 mg…2T..16 L.E -100 mg..2T..40 L.E GSK NO-MIGRAIN Z* (Zolmitriptan) 2.5,5 mg Tablet -2.5 mg..2T..18 L.E -5 mg……2T..35 L.E Amoun ZOMIG* (Zolmitriptan) 2.5 mg Tablet -3T….35 L.E Astra Zeneca Launched In 2010 SUMIGRAIN* (Sumatriptan) 25 mg Tablet -2T .... 8 L.E T3A AMIGRAWEST* (Zolmitriptan) 2.5 mg Film Coated Tablet -4T….20 L.E Western Ph.Ind Launched In 2010 RELPAX* (Elytriptan HCL) 40 mg Film Coated Tablet -3T….72 L.E Pfizer Declined In 2011
Image of page 75
TRIPTANS MARKET VALUE MAT 3/09 MAT 3/10 MAT 3/11 0 0.5 1 1.5 2 2.5 3 3.5 4 4.5 SALES/MILLIONS
Image of page 76
VALUE MARKET SHARE MAT 3/2009 52% 22% 19% 7% IMIGRAN NO-MIGRAIN Z RELPAX SUMIGRAN
Image of page 77
VALUE MARKET SHARE MAT 3/2010 44% 28% 17% 8% 3% IMIGRAN NO-MIGRAIN Z ZOMIG SUMIGRAIN AMIGRAWEST
Image of page 78
VALUE MARKET SHARE MAT 3/2011 34% 29% 26% 7% 4% AMIGRAN NO-MIGRAIN Z ZOMIG AMIGRAWEST SUMIGRAN
Image of page 79
SPECIALITIES-RXS CORELATION SPECIALITIES RXs NUMBER NEUROPSYCH. 11,110 GP 7,386 ENT 3,721 IM 2,940 SURGERY 2,517 CARDIOLOGY 1,021
Image of page 80
TRIPTANS RXS ANALYSIS TRIPTAN BRAND RXS NUMBER TARGETED SPEC. ZOMIG* (Zolmitriptan) 20,584 GP,N.P,ENT,IM, SURG., CARD. AMIGRAWEST* (Zolmitriptan) 2,535 NEURO-PSYCH. NO-MIGRAIN Z* (Zolmitriptan) 2,519 GP,NP,ENT SUMIGRAN* (Sumatriptan) 1,596 NP,GP,ENT MEGATAB* (Sumatriptan) 1,352 GYNECHOLOGY IMIGRAN* (Sumatriptan) 1,232 NP,GP,IM,ENT
Image of page 81
30,000 PRESCRIPTION
Image of page 82
CLINICAL TRIALS Crossover, double-blind clinical trial comparing Almotriptan and ergotamine plus caffeine for acute migraine therapy. Meta Analysis comparative study classifies Almotriptan as one of the best choices for the treatment of migraines.
Image of page 83
Image of page 84
Image of page 85
Image of page 86
Image of page 87
Image of page 88
Image of page 89
Image of page 90
Image of page 91
Image of page 96

You've reached the end of your free preview.

Want to read all 95 pages?

  • Fall '17

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

  • Left Quote Icon

    Student Picture

Stuck? We have tutors online 24/7 who can help you get unstuck.
A+ icon
Ask Expert Tutors You can ask You can ask You can ask (will expire )
Answers in as fast as 15 minutes